Quick Answer
Profound Medical Corp. reported R&D Expense of $20.60 million for fiscal year 2025.
Profound Medical Corp. R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2025 | $20.60M | +21.4% |
| 2024 | $16.96M | +17.6% |
| 2023 | $14.42M | — |
Quarterly R&D Expense
| Quarter Ending | R&D Expense | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $5.42M | +30.1% | -11.2% |
| June 30, 2025 | $6.10M | +45.0% | +26.8% |
| March 31, 2025 | $4.81M | +21.9% | +15.4% |
| September 30, 2024 | $4.17M | — | -0.9% |
| June 30, 2024 | $4.21M | — | +6.6% |
| March 31, 2024 | $3.94M | — | — |
- Profound Medical Corp. showed an increase of +21.4% in R&D Expense compared to the prior fiscal year.
- Over the 2023–2025 period, Profound Medical Corp.’s r&d expense has grown by 42.8% (from $14.42 million to $20.60 million).
- The most recent figure is from Profound Medical Corp.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 5, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: